AN OBSERVATIONAL STUDY OF AVASTIN (BEVACIZUMAB) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED OVARIAN CANCER

Trial Profile

AN OBSERVATIONAL STUDY OF AVASTIN (BEVACIZUMAB) AS FIRST LINE THERAPY IN PATIENTS WITH ADVANCED OVARIAN CANCER

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Bevacizumab (Primary)
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms OSCAR1
  • Sponsors Roche
  • Most Recent Events

    • 08 Jun 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Aug 2017.
    • 01 Jul 2015 Planned End Date changed from 1 Aug 2018 to 1 Aug 2017 as reported by ClinicalTrials.gov.
    • 29 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top